The cancer-suppressive effect of TP53 is primarily obtained by disrupting the Wnt/β-catenin pathway, thereby preventing transcription factor 4 (TCF4) from binding to the chromatin [29, 30]. This evidence concerns the gene TCF4 and cancer.